Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 2, 2011, Pages 757-761

  Song, Jae Min ^a   Van Rooijen, Nico ^b   Bozja, Jadranka ^c   Compans, Richard W ^a   Kang, Sang Moo ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c Zetra Biologicals   (United States)

Author keywords

M2 virus like particles; Supplemental vaccine

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; PROTEIN M2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; CROSS REACTION; DENDRITIC CELL; FEMALE; INFLUENZA A; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; LOW DRUG DOSE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEASONAL INFLUENZA; VIRUS LIKE AGENT; WEIGHT REDUCTION;

ANIMALS; CLODRONIC ACID; CROSS PROTECTION; DENDRITIC CELLS; FEMALE; HUMANS; INFLUENZA A VIRUS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA, HUMAN; MACROPHAGES; MICE; MICE, INBRED BALB C; VACCINATION; VIRAL MATRIX PROTEINS;

INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE;

EID: 79551658942     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1012199108     Document Type: Article

References (25)

1. de Jong MD, et al. (2005) Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 353:2667-2672.
2. Lamb RA, Zebedee SL, Richardson CD (1985) Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 40:627-633.
3. Feng J, et al. (2006) Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol J 3:102.
4. Fu TM, et al. (2009) Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 27:1440-1447.
5. Huleatt JW, et al. (2008) Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26:201-214.
6. Neirynck S, et al. (1999) A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat Med 5:1157-1163. (Pubitemid 29474420)
7. De Filette M, et al. (2006) The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 24:544-551. (Pubitemid 43017819)
8. Eliasson DG, et al. (2008) CTA1-M2e-DD: A novel mucosal adjuvant targeted influenza vaccine. Vaccine 26:1243-1252.
9. Mozdzanowska K, Zharikova D, Cudic M, Otvos L, GerhardW (2007) Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol J 4:118.
10. McGill J, Van Rooijen N, Legge KL (2008) Protective influenza-specific CD8 T cell responses require interactions with dendritic cells in the lungs. J Exp Med 205: 1635-1646. (Pubitemid 351962027)
11. Gómez-Puertas P, Albo C, Pérez-Pastrana E, Vivo A, Portela A (2000) Influenza virus matrix protein is the major driving force in virus budding. J Virol 74:11538-11547.
12. Latham T, Galarza JM (2001) Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J Virol 75: 6154-6165.
13. Chen BJ, Leser GP, Morita E, Lamb RA (2007) Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol 81:7111-7123.
14. Gessner JE, Heiken H, Tamm A, Schmidt RE (1998) The IgG Fc receptor family. Ann Hematol 76:231-248.
15. Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW (2001) Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 166:7381-7388.
16. Jegerlehner A, Schmitz N, Storni T, Bachmann MF (2004) Influenza A vaccine based on the extracellular domain of M2: Weak protection mediated via antibody-dependent NK cell activity. J Immunol 172:5598-5605.
17. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD (2008) A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 181:4168-4176.
18. Sambhara S, et al. (2001) Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 211:143-153.
19. Fu TM, et al. (2009) Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 385:218-226.
20. Rangel-Moreno J, et al. (2008) B cells promote resistance to heterosubtypic strains of influenza via multiple mechanisms. J Immunol 180:454-463.
21. Van Rooijen N, Sanders A (1994) Liposome mediated depletion of macrophages: Mechanism of action, preparation of liposomes and applications. J Immunol Methods 174:83-93. (Pubitemid 24297139)
22. Song JM, et al. (2010) Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 405:165-175.
23. Quan FS, Huang C, Compans RW, Kang SM (2007) Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 81:3514-3524. (Pubitemid 46456660)
24. Thepen T, McMenamin C, Oliver J, Kraal G, Holt PG (1991) Regulation of immune response to inhaled antigen by alveolar macrophages: Differential effects of in vivo alveolar macrophage elimination on the induction of tolerance vs. immunity. Eur J Immunol 21:2845-2850.
25. Bosio CM, Dow SW (2005) Francisella tularensis induces aberrant activation of pulmonary dendritic cells. J Immunol 175:6792-6801.